Highlight
- Risk-weighted apoB (RW-apoB) is a novel lipid metric that integrates weighted contributions of LDL, triglyceride-rich lipoproteins (TRL/remnants), and lipoprotein(a) [Lp(a)] to better predict coronary heart disease (CHD) risk.
- RW-apoB reclassifies individual CHD risk significantly compared to apoB alone, identifying high-risk individuals who would otherwise be misclassified by traditional apoB measurements.
- RW-apoB consistently outperforms apoB and other traditional lipid biomarkers in risk prediction across multiple large population cohorts, including statin-treated subjects, reflecting its potential for guiding clinical decision-making.
Study Background
Coronary heart disease remains a leading cause of morbidity and mortality worldwide. Accurate risk prediction is essential for timely preventive and therapeutic interventions. Traditionally, low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) have served as the primary biomarkers guiding cardiovascular risk assessment. However, these markers do not fully capture the atherogenic risk attributable to all apoB-containing lipoproteins. Apolipoprotein B (apoB), reflecting the total number of atherogenic particles, has been proposed as a superior predictor of CHD risk, but it may still underestimate risk when elevated levels of triglyceride-rich lipoproteins (TRL/remnants) and lipoprotein(a) [Lp(a)] are present. Given the distinct atherogenic potential of these lipoprotein subclasses, there is an unmet need for an integrated metric that better quantifies CHD risk by weighting the contributions of these particles according to their relative atherogenicity.
Study Design
This investigation utilized data from the UK Biobank and three additional large population cohorts to develop and validate a novel metric called risk-weighted apoB (RW-apoB). RW-apoB was formulated based on previously published estimates of the relative atherogenicity of LDL, TRL/remnants, and Lp(a) particles. RW-apoB calculates an atherogenicity-weighted sum as follows: RW-apoB = 11.65 × triglycerides (TG, mmol/L) + 0.215 × lipoprotein(a) (nmol/L) + 0.736 × apoB (mg/dL).
The study population included a diverse, large sample of adults, encompassing both statin-treated and untreated individuals, with longitudinal follow-up for incident CHD events. The primary endpoint was the occurrence of coronary heart disease events, verified via clinical records.
Key Findings
The application of RW-apoB substantially altered risk stratification compared to conventional apoB measurement. Specifically, 52% of individuals were reclassified by 10 or more percentile ranks when comparing RW-apoB to apoB. Notably, among individuals in the highest quintile of RW-apoB—characterized by elevated TRL/remnants and Lp(a)—the CHD event rate was 5.4%, yet many were clinically misclassified as lower risk by apoB alone.
Conversely, individuals in the top apoB quintile but with low TRL and Lp(a) levels demonstrated a lower observed event rate (3.9%) and were correctly down-ranked by RW-apoB, underscoring the metric’s refinement in risk discrimination.
Statistical analyses revealed that RW-apoB significantly increased Harrell’s C-index compared to apoB (P < .0001), indicating improved model discrimination. This superiority was consistent across all cohorts studied and extended to statin-treated subjects, where RW-apoB outperformed apoB as an index of residual risk. Cox proportional hazards models affirmed the independent predictive power of RW-apoB beyond traditional lipid measurements.
Expert Commentary
The development of RW-apoB addresses important limitations of existing lipid biomarkers by integrating the atherogenic burdens of diverse apoB-containing particles. This approach resonates with mechanistic insights recognizing that TRL/remnant particles and Lp(a) contribute disproportionately to atherosclerotic disease compared to LDL particles alone.
Clinicians and researchers have long sought improved risk stratification tools that transcend simplistic lipid measurement. RW-apoB’s demonstrated ability to reclassify risk, particularly identifying high-risk patients missed by conventional apoB, holds potential for enhancing personalized cardiovascular risk management. Furthermore, the metric’s utility in statin-treated patients highlights its relevance for assessing residual risk and guiding adjunctive therapies.
Limitations of the study include dependence on cohort data predominantly of European ancestry, which may affect generalizability to diverse populations. Future research should evaluate RW-apoB’s utility in clinical practice, its integration with existing risk algorithms, and assess cost-effectiveness of widespread testing.
Conclusion
Risk-weighted apoB (RW-apoB) represents an important advancement in lipid-based cardiovascular risk assessment. By accounting not only for particle number but also for the elevated atherogenicity of triglyceride-rich lipoproteins and Lp(a), RW-apoB substantially improves CHD risk stratification over traditional lipid biomarkers including apoB and LDL-C.
RW-apoB’s ability to more accurately identify individuals at heightened risk can inform personalized preventive strategies and therapeutic decisions, particularly in patients with mixed dyslipidemia or residual risk under statin therapy. These findings support RW-apoB’s potential translation into clinical practice and guideline incorporation pending further validation.
Funding and Clinical Trial Information
The study was conducted using UK Biobank data and supported by relevant grants from cardiovascular research foundations. There are no clinical trial registrations associated, as this was an observational cohort analysis and biomarker development study.
References
1. Rehman MB, Björnson E, Adiels M, et al. Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease. Eur Heart J. 2026 Jul 7;47(26):3415-3425. doi:10.1093/eurheartj/ehac123.
2. Langsted A, Nordestgaard BG. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2019;65(1):122-131.
3. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiol. 2019;4(12):1287-1295.
4. Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of triglyceride-rich lipoproteins: clinical implications. Eur Heart J. 2020;41(15):1419-1425.
5. Tsimikas S. A test in context: Lipoprotein(a) an independent risk factor for cardiovascular disease. J Am Coll Cardiol. 2017;69(6):692-711.
